GGrantIndex
Sort

21,453 grants matching tuberculosis

Core E Animal Infection Models

$941,758
David S Perlin · Hackensack University Medical Center · U19 · FY2019 · AI

Novel rifamycins to improve cure rates and shorten treatment of M. abscessus lung disease

$941,394
Thomas Dick · Hackensack University Medical Center · U19 · FY2025 · AI

Development of novel proteins synthesis inhibitors for MDR tuberculosis

$940,979
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2011 · AI

Immunotherapeutics and vaccines against anthrax, plague and tularemia

$940,978
Zheng W Chen · University Of Illinois At Chicago · U01 · FY2009 · AI

Immunotherapeutics and vaccines against anthrax, plague and tularemia

$940,299
Zheng W Chen · University Of Illinois At Chicago · U01 · FY2006 · AI

A micronized electrostatic precipitator for next-generation respiratory protection against pathogenic aerosols

$940,026
Julian Henley · Henley Ion, Llc · R44 · FY2023 · AI

IAS 2025. the 13th IAS Conference on HIV Science, Kigali, Rwanda, 14-17 July 2025

$940,000
Chris Beyrer · Ias · R13 · FY2025 · AI

RP3: Targeting ATG gene-dependent immunity for novel anti-infective therapeutics

$939,459
Seungmin Hwang · Ut Southwestern Medical Center · U19 · FY2023 · AI

Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis

$939,379
Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2019 · AI

UCB/UCSF AIDS International Training and Research Program (AITRP)

$939,335
Arthur L. Reingold · University Of California Berkeley · D43 · FY2010 · TW

M. tuberculosis carbon metabolism during infection

$939,332
Sabine Ehrt · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · AI

Advanced Mass Spectrometry Facility

$938,947
David Anderson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIC · FY2009 · DK

Discovery and validation of drug resistance mutations

$938,261
Eric H. Rubin · Harvard Medical School · U19 · FY2018 · AI

Gene Regulation In The Immune System

$937,804
Keiko Ozato · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2013 · HD

PS05-003 TUBERCULOSIS ELIMINATION AND LABORATORY

$937,658
Karyn L Berry · District Of Columbia Dept Of Human Srvs · U52 · FY2007 · PS

Microsensor Arrays for Saliva Diagnostics

$937,339
Tufts University Medford · U01 · FY2003 · DE

Clinical Core

$936,892
Daniel W Fitzgerald · Weill Medical Coll Of Cornell Univ · U19 · FY2015 · AI

Development of novel proteins synthesis inhibitors for MDR tuberculosis

$936,466
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2013 · AI

Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals

$936,265
Richard E Chaisson · Johns Hopkins University · U01 · FY2021 · AI

Microsensor Arrays for Saliva Diagnostics

$935,857
Tufts University Medford · U01 · FY2004 · DE

Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease

$935,638
Padmini Salgame · Rutgers Biomedical And Health Sciences · U19 · FY2024 · AI

New anti-tubercular agents targeting intracellular bacteria

$935,324
Tanya Parish · Seattle Children'S Hospital · R01 · FY2024 · AI

Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection

$934,898
Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2024 · AI

TRAINING AND RESEARCH IN HIV PREVENTION IN RUSSIA

$934,129
Yale University · D43 · FY2003 · TW

Core 1: Facility Management, Maintenance and Operations Core

$933,206
Colin S. Duckett · Duke University · UC7 · FY2023 · AI